99mTc标记COI配合物的制备及其用作心室显像剂的初步研究

通过改变异腈配体的结构和配合物的中心核,以期获得标记方法简单、放化纯度高以及生物性能优良的新型心室显像剂.以环辛胺为原料,通过甲酰胺化和脱水两步反应制得配体环辛基异腈(COI),并以氯化亚锡为还原剂和二硫代肼基甲酸甲酯为供氮体,通过配体交换反应得到放化纯度大于95%的^99mTcN-COI标记物.以氯化亚锡为还原剂直接标记制得放化纯度大于95%的^99mTc-COI配合物.两种标记物在室温下放置6h以上,其放化纯度无明显变化.在正常昆明小鼠体内进行的生物分布实验研究结果显示,^99mTcN-COI和^99mTc-COI在心脑中有一定摄取,但肝、肺及血等本底摄取相对较高.二者在血液中都有很高的浓集,且滞留也很好,其中^99mTc-COI配合物在静脉注射后60min时的血/心、血/肝和血/肺摄取比分别为6.67,1.54和2.07,有望成为一种新型的制备方法简单的心室显像剂.     

用于肿瘤显像的99mTc标记葡萄糖衍生物的合成与生物评价

研制性能良好、制备简便且价格低廉的新型肿瘤SPECT显像剂是国际放射性药物领域的重点前沿课题.^99mTc是临床应用最多的SPECT核素.为了研制新型^99mTc标记的肿瘤放射性药物,本研究合成了一种含异腈的葡萄糖衍生物(CN6DG),并将其用^99mTc标记得到放射化学纯度大于95%的^99mTc–CN6DG配合物.该配合物为水溶性物质(log D为-2.52±0.33)且具有良好的体内外稳定性.体外细胞摄取实验结果表明其进入肿瘤细胞与葡萄糖转运体相关.其在S180荷瘤小鼠中注射2 h后肿瘤摄取值为0.75±0.12%ID/g,肿瘤/肌肉和肿瘤/血液的比值分别为4.41, 18.75.在A549荷瘤小鼠中注射2 h后肿瘤摄取值为2.62±0.23%ID/g,优于^99mTc–CN5DG (1.48±0.23%ID/g),肿瘤/血液比值(52.4 vs. 49.33)和肿瘤/肌肉比值(6.89 vs. 24.67)具有和^99mTc–CN5DG同样优良的结果.在S18...     

99mTcN(PNP5)(NOEt)]+新型心肌灌注显像剂研究

以氯化亚锡为还原剂,SDH(丁二酰二酰肼)为供氮体,经配体交换反应得到[^99mTcN(PNP5)·(NOEt)]⁺,通过TLC和HPLC分析,其放化纯度大于90%.该标记物是一种体外稳定性良好的阳离子配合物,在小鼠和狗体内的心肌初始摄取量高,滞留好,肝和肺等非靶组织清除快,有利于早期心肌显像,有望成为一种新型的心肌灌注显像剂.     

具有α, β-不饱和酮的2-吲哚酮衍生物的设计、合成及抗肿瘤活性

以2-吲哚酮衍生物(1a~1c)与醛(2a~2n)为原料,通过克脑文格尔反应和酰化反应得到17个(E)-1-乙酰基亚苄基吲哚酮衍生物(1~17),其结构经¹HNMR、 ¹³CNMR和MS(ESI)进行表征。采用CTG法评价了目标化合物1~17对人非小细胞肺癌细胞(A-549),人乳腺癌细胞(MCF-7)和人胃腺癌细胞(BGC-823)3种肿瘤细胞增殖的抑制活性。结果表明：化合物16对三种肿瘤细胞具有显著的抑制活性,IC₅₀值分别为0.50±0.03(A549)、 0.20±0.02(MCF-7)和0.34±0.04μM(BGC-823),尤其是对MCF-7的抗增殖活性与阳性对照阿霉素相当。      

柠檬酸镧诱导肿瘤细胞凋亡的研究

采用噻唑蓝(MTT)法检测稀土化合物柠檬酸镧在1×10-3～5 mmol·L-1浓度范围内对体外培养的人乳腺癌细胞株MCF-7、前列腺癌细胞株PC-3、肝癌细胞株HepG2和宫颈癌细胞株HeLa生长的影响.结果表明,柠檬酸镧对各种癌细胞生长的影响存在浓度依赖性,在实验浓度范围内,低浓度无明显作用特征,高浓度抑制癌细胞生长;不同肿瘤细胞对稀土的响应不同,HeLa细胞相对敏感,其IC50值为(0.16±0.08)mmol·L-1,而MCF-7细胞为(0.18±0.02)mmol·L-1,PC-3细胞为(1.55±0.45)mmol·L-1,HepG2细胞为(2.71±0.11)mmol·L-1.进一步以0.15 mmol·L-1的柠檬酸镧作用于HeLa细胞,采用Hoechst 33258荧光染色、PI单染流式细胞仪检测、Annexin V-FITC/PI双染色法观察镧对HeLa细胞的毒性作用.结果表明,柠檬酸镧作用24 h后,HeLB细胞出现明显的凋亡特征,PI染色流式细胞仪检测可见凋亡峰,细胞周期分析表明sub-G1期细胞硅著增加,G0/G1期细胞显著减少(P<0.05),Annexin V-FITC/PI双染检测细胞凋亡率为(61.65±4.60)%(P<0.05).上述结果表明柠檬酸镧能诱导癌细胞发生凋亡.以HeLa细胞最灵敏而对HepG2并不敏感,其次序为HeLa>McF-7>Pc-3>HepG2.     

利用噬菌体展示技术筛选放射性标记肺癌靶肽YC11及其生物分布

利用体内噬菌体展示技术筛选了肿瘤特异性结合靶肽, 获得了肺腺癌靶肽CSIHYPLSC(YC11)并对其进行了放射性碘标记. 采用反相高效液相色谱技术(RP-HPLC)分离纯化¹³¹I-YC11和对照肽¹³¹I-NGR, 放化纯度大于99%. 在荷人肺腺癌A549裸鼠体内的分布结果表明, ¹³¹I-YC11的肿瘤/血液放射性计数比为0.62, 肿瘤/心脏放射性计数比为2.06, 肿瘤/肺放射性计数比为1.11, 肿瘤/肝脏放射性计数比为0.81, 略高于¹³¹I-NGR的对应值. ¹³¹I-YC11在肿瘤中的摄取值为2.79%ID/g, 与¹³¹I-NGR在肿瘤中的摄取值(1.61%ID/g)相比, ¹³¹I-YC11的肿瘤摄取高于多肽¹³¹I-NGR.     

新型1,3-二取代酞嗪酮类衍生物的合成及抗肿瘤活性研究

为了寻找高效低毒的抗肿瘤药物,设计并合成新型的1,3位取代酞嗪酮类化合物.采用噻唑蓝(MTT)法对目标化合物在MCF-7(人乳腺癌细胞)、PC-3(人前列腺癌细胞)、SW-620(人结肠癌细胞)和HGC-27(人胃癌细胞)四种人类癌细胞的抗增殖活性进行评价.结果显示大部分化合物具有较好的抗增殖活性.其中,2-(4-(4-溴苯基)-1-氧代酞嗪-2(1H)-基)-N-(2-氟苯基)乙酰胺(5g)对MCF-7细胞的抗增殖活性较好,IC50值为6.01μmol/L,为抗肿瘤药物的研究提供了思路.     

新型16-E-苯亚甲基甾体衍生物的合成及其抗癌活性

以雄烯二酮为底物,通过2,3-二氯-5,6-二氰基-1,4-苯醌脱氢和羟醛缩合反应合成了一系列新的16-E-苯亚甲基甾体衍生物（4a~4k）,其结构经¹H NMR, ¹³C NMR和HR-MS(ESI)表征。并采用MTT法考察了化合物对人体宫颈癌细胞（Hela）和乳腺癌细胞（MCF-7）的增殖抑制活性。结果表明：浓度为30 μg·mL^-1时,化合物4b具有较强的抑制MCF-7细胞增殖的活性,抑制率46%。     

载药荧光纳米粒子的制备及在乳腺癌MCF-7细胞系的应用及效果评价

利用两亲性聚乙二醇-聚乳酸共聚物（PEG-PDLLA）包覆荧光染料（DPBA）和紫杉醇（PTX）,通过自组装方法制得载药荧光纳米粒子DPBA/PTX@PEG-PDLLA.纳米粒子尺寸均一,具有良好的生物相容性.对纳米粒子的发光性质、载药量和体外药物释放等进行了表征,并考察了纳米粒子对乳腺癌细胞MCF-7的抑制效果,观察了MCF-7细胞对纳米粒子的摄取情况.结果表明,DPBA/PTX@PEG-PDLLA纳米粒子具有较强的红光发射,不仅可以用于MCF-7肿瘤细胞质荧光成像,而且对肿瘤细胞的增殖具有一定的抑制能力.     

新型4-取代苯胺喹唑啉衍生物的合成与抗肿瘤活性研究

以6-碘喹唑啉-4-酮为原料,经氯代、胺化、Suzuki偶联、Wittig-horner等反应合成了7个新型的4 取代苯胺喹唑啉衍生物(5a~5g),其结构经¹H NMR和HR-MS(ESI)表征。采用MTT法研究了5a~5g对人乳腺癌细胞(MCF-7)、人肺癌细胞(A549)和人皮肤鳞癌细胞（A431）的抑制活性。结果表明：5a~5g对肿瘤细胞均具有明显的抑制活性;其中5e的抑制活性(IC₅₀=0.13~5.26 μmol·L^-1)优于拉帕替尼(IC₅₀=0.21~15.56 μmol·L^-1)。     

Radiosynthesis of N-11C-meisoindigotin as a novel PET agent for imaging of cyclin-dependent kinases and GSK-3β

Meisoindigotin has been demonstrated as a new type of cancer chemotherapeutic agent. N-11C-Meisoindigotin was synthesized by N-11C-methylation of the isoindigotin precursor with 11C-labelled methyl triflate. The decay corrected radiochemical yields were 15−25 % ,and the specific radioactivity was 1.0−1.2 Ci/?mol at the end of synthesis. The cellular uptake of [N-11C]meisoindigotin was evaluated in four different lung cancer cell lines. Our results showed that the A549, GLC-82, 95D cell lines exhibited higher uptake than 95C cell line after incubation for 60 min. N-11C-Meisoindigotin was a promising candidate for further development as a novel PET radiotracer for imaging of cyclin-dependent kinases (CDKs) and GSK-3β.     

Tumor targeting of HPMA copolymer conjugates containing sulfadiazine groups

To develop new tumor targeting macromolecular conjugates,poly（HPMA）-SD-APMA-DTPA（HPMA:N-（2-hydroxypropyl）- methacrylamide;APMA:N-（3-ammopropyl）methacrylamide;DTPA:diethylenetriaminepentaacetic acid;SD:sulfadiazine） was synthesized and characterized.The poly（HPMA）-SD-DTPA conjugates were radiolabeled with the radionuclide ^99mTc and tested for uptake by cultured H22 cells in vitro.DTPA-^99mTc（radiotracer 1） and poly（HPMA）-DTPA-^99mTc（radiotracer 2） were also synthesized and characterized for comparison.The uptake of poly（HPMA）-SD-DTPA-^99mTc（radiotracer 3,34.76%） was significantly higher than that of poly（HPMA）-DTPA-^99mTc（16.40%）,indicating that uptake of the poly（HPMA）-SD-DTPA-^99mT was active binding.The uptake of poly（HPMA）-DTPA-^99mTc was significantly higher than that of DTPA-^99mTc（2.98%）, suggesting that uptake of the poly（HPMA）-DTPA-^99mT was passive binding.The data suggest that the poly（HPMA）-SDAPMA -DTPA conjugates might be useful as tumor targeting macromolecular conjugates.     

In vitro evaluation of apoptosis detection by 99mTc-tetrofosmin in MCF-7 breast cancer cell line

Radiolabeled molecules have an important role to evaluate tumor characteristics such as aggressiveness, and to identify the effectiveness of cancer treatments such as chemotherapy and radiotherapy. Various radionuclide (¹⁸F, ^99mTc, ¹²⁴I) labeled molecules can be used apoptosis detection by estimating decrescendos cell viability after therapy. ^99mTc-tetrofosmin which is used as a myocardial perfusion imaging agent in routine and at the same time is known to accumulate in various tumors including breast tumor. The aim of this study was to assess the utility of ^99mTc-tetrofosmin for monitoring the early response of MCF-7 breast cancer to chemotherapy. To evaluate the role of ^99mTc-tetrofosmin in vitro chemotherapy, the uptake ratio was determined using MCF-7 breast cancer line after the cells had been treated with cisplatin. When we examined the apoptotic ratios which induced with different dose of cisplatin in MCF-7 breast cancer cells by using Annexin V and TUNEL methods, it was observed that the rate of apoptosis increased with soaring dose. The uptake rates of ^99mTc-tetrofosmin in MCF-7 cell line in the chemotherapeutic groups were lower than it is in the control group (p < 0.01). The negative correlation between uptake ratios and apoptotic rates shows that ^99mTc-tetrofosmin may be used a radiopharmaceutical for evaluating chemotherapy response. ^99mTc-tetrofosmin might be probably useful as an imaging agent for estimation of early chemotherapy response in breast cancer.     

Novel 99mTc labeled σ receptor ligand as a potential tumor imaging agent

A novel 99mTc labeled complex, [N-[2-((2-oxo-2-(4-(3-phenylpropyl)piperazin-1-yl)ethyl) (2-mercaptoethyl)amino)acetyl]-2-aminoethanethiolato]Technetium(V) oxide (PPPE-MAMA′-99mTcO) ([99mTc]-2) has been designed and prepared based on the integrated approach. The corresponding rhenium complex (PPPE-MAMA′-ReO)(Re-2) has been prepared and characterized. In vitro competition binding assays show moderate affinity of Re-2 towards σ1 and σ2 receptors with Ki values of 8.67 ± 0.07 and 5.71 ± 1.88 μmol, respectively. Planar images obtained at 0.5 h, 4 h, 20 h after I.v. Injection indicate the accumulation of [99mTc]-2 in MCF-7 human breast tumor bearing mice at 20 h. Furthermore, the accumulation of [99mTc]-2 has been inhibited at 20 h after co-injection of [99mTc]-2 plus haloperidol (1 mg/kg). Biodistribution studies of [99mTc]-2 display an in vivo tumor uptake of 0.14% ± 0.01% ID/g at 24 h post I.v. Injection with a tumor/muscle ratio of 6.02 ± 0.87. The above results suggest that [99mTc]-2, derived from a previously published lead compound, retains certain tumor uptake and affinity for σ receptors. [99mTc]-2 may be used as a basis for further structural modifications to develop tumor imaging agents with high affinity for σ receptors.     

Measurement of Tumor Vascular Damage in Mice with 99m Tc-MIBI Following Photodynamic Therapy

Abstract— The clinical perfusion agent ^99mTc-MIBI was used to monitor changes in tumor vascular perfusion (TVP) induced by Photofrin® (Pll)-mediated photodynamic therapy (PDT). BALB/c mice bearing an EMT-6 tumor on each hind thigh were given an intravenous injection of 1, 2 or 5 mg kg⁻¹ PII. Twenty-four hours later, one tumor was illuminated (600–650 run, 200 mW cm⁻² 400 J cm⁻²) while the other served as a control. At various time intervals after PDT (0, 2 and 24 h) mice received an intravenous injection of ^99mTc-hexakismethoxy(sobutyusonitri-le (MIBI) (0.18 MBq g⁻¹) and were sacrificed 2 min later. The light-treated and the untreated tumors were then dissected, the radioactivity was counted and the percentage of the injected dose per gram of tumor (%ID g⁻¹) was calculated as a measure of TVP. We observed that TVP is drug dose dependent, develops progressively with time post-PDT and is inversely related to PDT efficacy. Our data show that early tumor retention of ^99mMIBI is a simple method to assess TVP and vascular damage induced by PDT.     

阿糖胞苷金属卟啉衍生物的合成及光动力抗肿瘤活性

设计并合成了阿糖胞苷卟啉衍生物(AHP), 并通过金属插入反应获得了4种金属卟啉衍生物, 采用核磁共振、红外光谱、紫外-可见光谱和质谱等手段对化合物的结构进行了表征.光动力抗肿瘤活性实验结果表明, 含药浓度为25 μmol/L的ZnAHP经光照30 min后对人乳腺癌MCF-7细胞的光动力杀伤率平均达(45.86±8.20)%.     

Synthesis of chalcones with anticancer activities

Several chalcones were synthesized and their in vitro cytotoxicity against various human cell lines, including human breast adenocarcinoma cell line MCF-7, human lung adenocarcinoma cell line A549, human prostate cancer cell line PC3, human adenocarcinoma cell line HT-29 (colorectal cancer) and human normal liver cell line WRL-68 was evaluated. Most of the compounds being active cytotoxic agents, four of them with minimal IC?? values were chosen and studied in detail with MCF-7 cells. The compounds 1, 5, 23, and 25 were capable in eliciting apoptosis in MCF-7 cells as shown by multiparameter cytotoxicity assay and caspase-3/7, -8, and -9 activities (p < 0.05). The ROS level showed 1.3-fold increase (p < 0.05) at the low concentrations used and thus it was concluded that the compounds increased the ROS level eventually leading to apoptosis in MCF-7 cells through intrinsic as well as extrinsic pathways.     

Covalent Organic Frameworks(COFs) for Sequestration of99TcO4–

Covalent organic frameworks(COFs), as a class of crystalline porous materials with periodic lattices and porous structures, have received extensive attention in the fields of gas storage and separation, energy storage, catalysis and optoelectronics and so on. However, COFs are still in their infancy in the field of nuclear waste treatment, especially for sequestration of long-live problematic radionuclides, such as ⁹⁹Tc. Battle of decontamination of pertechnetate(TcO₄^–), a main existence of ⁹⁹Tc under aerobic environments, is far from finished. In this review, recent progresses of COFs and some relative materials in the sequestration of pertechnetate, and perspective on surmounting the unmet issues are elucidated.     

An Efficient One-pot Synthesis of Certain Stereoselective Spiro[pyrazole-4,5'-isoxazoline]-5-one Derivatives: In vitro Evaluation of Antitumor Activities,Molecular Docking and In silico ADME Predictions

A library of novel spiro[pyrazole-4,5'-isoxazoline]-5-one derivatives were designed and synthesized using a concise and efficient one-pot reaction protocol through 1,3-dipolar cycloaddition between 4-benzylidene-3-methyl-1-phenyl-1H-pyrazol-5(4H)-one and chlorooximes. The synthesized derivatives were elucidated and characterized based on their spectroscopic data, including infrared spectrometry(IR), ¹H NMR, ¹³C NMR, and elemental and mass spectral analysis. The synthesized compounds were evaluated for their antitumor inhibition potency against four human cancer cell lines, including human prostatic adenocarcinoma (PC3), human colorectal carcinoma(HCT116), human liver hepatocellular carcinoma(HepG2) and breast adenocarcinoma (MCF7). The outcomes were compared with the standard reference drug Doxorubicin. Among the synthesized chlorooximes, compounds 6d and 6e were the most active compounds on all cell lines. The spiro[pyrazole-4,5'-isoxazoline]-5-one derivatives 7a and 7c were active on the HepG2 liver cancer cell line. In comparison, compounds 7f and 7g were moderately active on the MCF7 cell line. The structure-activity relationship was explored for the synthesized compounds. Besides, in silico analysis of physicochemical, adsorption, distribution, metabolism, excretion and toxicity(ADMET) properties were done to determine the potential capacity of drug candidates. Molecular docking study onto the epidermal growth factor(EGF) tyrosine kinase receptor(3POZ) was done for the most active compounds to validate the reliability of in vitro anticancer screenings.